Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies.

ABSTRACT: Dementia with Lewy bodies (DLB), a progressive neurodegenerative disease with heterogeneous clinical presentations, greatly impacts patients, caregivers, and society. Despite its frequency, diagnosing and treating DLB remains challenging. Advances in in vivo biomarker assays reflecting underlying pathology are improving disease identification, diagnostic accuracy, and therapeutic development for biologically targeted, disease-modifying agents. Consequently, definitions of Alzheimer's disease and Parkinson's disease (PD) have shifted to focus on pathological changes occurring before clinical features, with proposed frameworks for detecting pathological amyloid and tau, neurodegeneration, and other markers (National Institute on Aging-Alzheimer's Association) and alpha-synucleinopathy and do

SUBMITTER: Goldman JG 

PROVIDER: S-EPMC12276075 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature